A survey of more than 100 studies involving PIB-PET, a diagnostic tool that involves injecting a radiotracer called Pittsburgh compound B into the brain via the bloodstream, and imaging the brain with positron emission tomography (PET), has confirmed its sensitivity in detecting amyloid-beta protein plaques. The tool is not yet commercially available. The study also provides strong evidence supporting the theory that accumulation of amyloid-beta protein plaques in the brain is central to the development of Alzheimer’s. The findings, that amyloid deposits appear to reach a plateau early in the disease course, may explain why Alzheimer's patients have not responded to promising experimental drugs that target amyloid. It may be that they are being administered too late.
Review confirms early diagnosis tool
Reference
Rabinovici, G., & Jagust, W. J. (2009). Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behavioural Neurology, 21(1), 117-128. Retrieved from http://dx.doi.org/10.3233/BEN-2009-0232
Related News
Late-life depression increases dementia risk
Submitted by Fiona McPherson
on
Late-life depression is associated with an increased risk for all-cause dementia, Alzheimer’s disease, and, most predominantly, vascular dementia, a new study shows.
A new meta-analysis extends previous research showing a link between depression and Alzheimer’s disease to late-life depression and dementia. The analysis of 23 studies concluded that those with late-life depression were significantly more likely to develop dementia (1.85 times more likely), and that the risk of developing vascular dementia was significantly greater than that of developing Alzheimer’s (2.52 vs 1.65).
Alzheimer's disease symptoms more subtle in people over 80
A study involving 105 people with Alzheimer's disease and 125 healthy older adults has compared cognitive function and brain shrinkage in those aged 60-75 and those aged 80+.
Diagnosis and prevalence of dementia & MCI — recent reports
Functional impairment good indicator of mild cognitive impairment
Alzheimer's diagnostic guidelines updated
For the first time in 27 years, clinical diagnostic criteria for Alzheimer's disease dementia have been revised, and research guidelines updated. They mark a major change in how experts think about and study Alzheimer's disease.
The updated guidelines now cover three distinct stages of Alzheimer's disease:
New test to diagnose early stage Alzheimer's disease
A new test has been developed that measures amyloid-beta oligomers in the cerebrospinal fluid, promising a reliable means of early diagnosis. In a comparison of patients with Alzheimer’s, patients with MCI that later developed into Alzheimer’s, and controls, levels of these protein fragments directly correlated with Alzheimer’s, and was more accurate than levels of the more usual amyloid plaques.
Blood test predicts Alzheimer’s risk early
Submitted by Fiona McPherson
on
A five-year study involving 525 older adults (70+) found 46 had Alzheimer’s or aMCI and a further 28 went on to develop the conditions. The blood levels of 10 specific lipids predicted with more than 90% accuracy whether an individual would go on to develop either Alzheimer’s or aMCI within 2-3 years. The researchers speculate that the lower lipid levels could be an early indication that brain cells are beginning to lose their integrity and break down.
Tracking preclinical Alzheimer's progression
Submitted by Fiona McPherson
on
New research supports the classification system for preclinical Alzheimer’s proposed two years ago. The classification system divides preclinical Alzheimer's into three stages:
Stage 1: Levels of amyloid beta begin to decrease in the spinal fluid. This indicates that the substance is beginning to form plaques in the brain.
Stage 2: Levels of tau protein start to increase in the spinal fluid, indicating that brain cells are beginning to die. Amyloid beta levels are still abnormal and may continue to fall.
New biomarker shows Alzheimer's disease long before symptoms
Submitted by Fiona McPherson
on
Analysis of mitochondrial DNA (mtDNA) in the cerebrospinal fluid has found that both symptomatic Alzheimer’s patients and asymptomatic patients at risk of Alzheimer’s showed a significant decrease in levels of circulating cell-free mtDNA in the CSF. Patients with frontotemporal dementia did not display this.
Diagnosing MCI at home
Following on from a previous study showing that such a virtual supermarket game administered by a trained professional can detect MCI, a small study used a modified Virtual SuperMarket Remote Assessment Routine (VSM-RAR) that was self-administered by the patient at home on their own, for a period of one month.
Using the average score over 20 assessments, the game correctly diagnosed MCI 91.8% of the time, a level of diagnostic accuracy similar to the most accurate standardized neuropsychological tests.
Predicting if MCI will progress to Alzheimer's
Submitted by Fiona McPherson
on
A French study has predicted with 90% accuracy which patients with mild cognitive impairment would receive a clinical diagnosis of Alzheimer's disease within the following two years. The best neurological predictors were cortical thickness in two brain regions (the right anterior cingulate and middle frontal gyri), and the best cognitive predictors were deficits in both free recall and recognition episodic memory. Combining these measures achieved the highest accuracy.